Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
Mizuho Securities analyst Difei Yang downgraded Spark Therapeutics (NASDAQ: ONCE) from Buy to Neutral with a price target of $114.50.
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $113.85 yesterday.